Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Revenue | 15M | 28% |
| Gross Profit | 3.6M | 55.5% |
| Cost of Revenue | 12M | 21.4% |
| Operating expense | 44M | 30.4% |
| Net Income | -25M | 39.2% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 376M | 1.3% |
| Total Liabilities | 133M | 0.5% |
| Total Equity | 243M | 1.8% |
| Shares Outstanding | 71M | 2.5% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | -24M | 385.2% |
| Cash from investing | 160,000 | 101.4% |
| Cash from financing | 11M | 7682.2% |
EPS
Financial Highlights for C4 Therapeutics in Q3 '24
C4 Therapeutics reported a revenue of 15M, which is a 28% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 3.6M, marking a 55.5% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 12M, a 21.4% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 44M, showing a 30.4% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -25M, showing a -39.2% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
C4 Therapeutics faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. Higher operating expenses might indicate increased investments or potential inefficiencies.
